Results 11 to 20 of about 257,683 (336)

A Study on the Alteration of Endoplasmic Reticulum Stress-related Proteins in Cyclophosphamide-induced Damage to Urothelium [PDF]

Pharmaceutical and Biomedical Research, 2023
Background: Cyclophosphamide is widely prescribed as an anti-cancer drug and used as an immunosuppressant. Hemorrhagic cystitis is one of the common complications of cyclophosphamide intake.
Hemalatha R, Muthuraman N, Sandya Rani, Premila Abraham   +3 more
doaj  

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. [PDF]

PLoS ONE, 2014
BACKGROUND: Hematopoietic stem cell transplantation is a curative treatment for several haematological malignancies. However, treatment related morbidity and mortality still is a limiting factor.
Ibrahim El-Serafi, Manuchehr Abedi-Valugerdi, Zuzana Potácová, Parvaneh Afsharian, Jonas Mattsson, Ali Moshfegh, Moustapha Hassan   +6 more
doaj   +1 more source

Platelet Augmentation Potential of Polyherbal Formulation in Cyclophosphamide-Induced Thrombocytopenia in Wistar Rats [PDF]

Folia Medica, 2021
Introduction: Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. Several medicinal plants possess curative and protective effect against thrombocytopenia associated with diseases
Girish Sailor, Komal Hirani, Ghanshyam Parmar, Rajesh Maheshwari, Rupa Singh, Avinash Kumar Seth   +5 more
doaj   +3 more sources

Nephrotoxicity Risk of Cyclophosphamide in Lupus Model

Journal of Tropical Pharmacy and Chemistry, 2021
Cyclophosphamide is one of the standard therapies for lupus, especially lupus nephritis based on its immunosuppressive effect. However, cyclophosphamide is also known as a nephrotoxic agent.
Niken Indriyanti
doaj   +1 more source

Long-Term Effects of Cyclophosphamide in Sustained Remission in Childhood Steroid-resistant Nephrotic Syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2022
Nephrotic syndrome (NS) is a chronic renal disease that can progress into end-stage renal disease within 5 years if no remission occurs. Achieving optimal remission is important to obtain better outcomes of treating childhood steroid-resistant NS (SRNS).
Eka L Hidayati, Dimas D Saputro, Laksmi Bestari, Zakiudin Munasir, Achmad Rafli   +4 more
doaj   +1 more source

Metabolism of cyclophosphamide [PDF]

Cancer, 1967
The in vivo activation of cyclophosphamide (Endoxan) to cytostatic and alkylating metabolites has been studied. Endoxan is metabolized to the weak anion by microsomal dealkylation in the rat's liver; this product is the first alkylating metabolite.
N. Brock, H.-J. Hohorst
openaire   +3 more sources

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Neoplasia: An International Journal for Oncology Research, 2011
Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to conventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by antiangiogenic mechanisms of action and
Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel   +6 more
doaj   +1 more source

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

New England Journal of Medicine, 2010
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years.
John H. Stone, Peter A. Merkel, R. Spiera, P. Seo, C. Langford, G. Hoffman, C. Kallenberg, E. St. Clair, A. Turkiewicz, N. Tchao, L. Webber, L. Ding, Lourdes P. Sejismundo, Kathleen Mieras, D. Weitzenkamp, D. Ikle, V. Seyfert-Margolis, Mark Mueller, P. Brunetta, Nancy B. Allen, F. Fervenza, D. Geetha, K. Keogh, E. Kissin, P. Monach, T. Peikert, C. Stegeman, S. Ytterberg, U. Specks   +28 more
semanticscholar   +1 more source

Post-transplant cyclophosphamide-induced cardiotoxicity: A comprehensive review [PDF]

Journal of Cardiovascular and Thoracic Research
Cyclophosphamide-induced cardiotoxicity, associated with its toxic metabolite acrolein, is a significant concern and unresolved issue, especially when cyclophosphamide is administrated in high doses.
Azin Alizadehasl, Bita Shahrami, Reza Rahbarghazi, Azam Yalameh Aliabadi, Seyedeh Fatemeh Hosseini Jebelli, Yasamin Afsari Zonooz, Hoda Hakimian, Farzaneh Fathi, Sara Forati, Aysa Rezabakhsh   +9 more
doaj   +1 more source

Cognitive impairment and elevated peripheral cytokines in breast cancer patients receiving chemotherapy

Arquivos de Neuro-Psiquiatria, 2022
Background Anthracyclines-based regimen (5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); cyclophosphamide, epirubicin, and 5-fluorouracil [CEF]) and non-anthracycline based regimens (cyclophosphamide, methotrexate, and 5-fluorouracil [
Mohd Ashif Khan, Dinesh Bhurani, Ubedul Hoda, Nouroz Sehar, Nidhi Agarwal   +4 more
doaj   +1 more source